Britain and America have agreed to a significant trade agreement that will keep zero duties on UK medicine exports entering the US market.
Agreement Details of the Accord
As part of the deal, the UK has committed to raise expenditure on drugs through the National Health Service (NHS). This move ensures that import taxes on these vital products will stay at zero for a period of the next three years.
This agreement follows earlier threats to hike import taxes on branded drug products, with figures mentioned as high as double the cost.
"This arrangement between the UK reinforces the worldwide climate for cutting-edge drugs and introduces long-overdue equity to transatlantic pharmaceutical trade," a release noted.
Trade Impact
Drugs are one of the Britain's largest exports to the US, which is clearly the biggest destination for major companies like GSK and AstraZeneca.
Export figures show that in the 12 months prior to last September, the UK exported medicines totaling over eleven billion pounds to the US. This figure represented nearly one-fifth of total UK exports in that span.
"This guarantee safeguards employment, increases funding and facilitates the UK to emerge as a worldwide center for medical research," the Business and Trade Secretary stated.
Detailed British Pledges
The agreement involves several specific commitments from the UK:
- Higher Cost Ceiling: The UK will raise the affordability limit at which it considers new treatments to be too expensive by a quarter.
- Boosted Medicine Funding: There is a goal to double total public funding on drugs from 0.3 percent of GDP to 0.6 percent over the coming ten years.
- Payback Limit: The sum pharmaceutical firms must refund to the NHS to prevent overspending will be limited at 15%. Last year, refunds topped 20%.
Industry Background
The deal follows a protracted tension between the sector and the British authorities over spending levels and NHS adoption.
These tensions were exacerbated by assertions that American patients were paying several times more for the identical medicines than people in the Britain and the EU.
Over the last 18 months, several large manufacturing plans in the UK have been delayed or scrapped, while substantial investments have been directed toward projects in the United States.
A senior figure publicly accepted that the NHS needed to invest a greater share on treatments, noting that its spending on drugs had shrunk as a proportion of its total funding over the previous ten-year period.
